Altimmune to Participate at Leerink Partners Therapeutics Forum

July 2, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403

Julia Weilman
Burns McClellan
Phone: 646-732-4443

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657

Primary Logo

Source: Altimmune, Inc


Investor Contact


Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail